This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xia, M.
Right arrow Articles by Stamm, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xia, M.
Right arrow Articles by Stamm, W. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3974-3976, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3974-3976.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis

Minsheng Xia,1 Robert J. Suchland,1 Joli A. Carswell,1 John Van Duzer,2 Debra K. Buxton,2 Kara Brown,2 David M. Rothstein,2 and Walter E. Stamm1*

Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195,1 ActivBiotics, Inc., Lexington, Massachusetts 024212

Received 1 February 2005/ Returned for modification 28 February 2005/ Accepted 25 April 2005

Rifalazil, a semisynthetic rifamycin, was shown previously to have exceptional potency against Chlamydia trachomatis (MIC of 0.00025 µg/ml). We therefore tested 250 additional rifamycin derivatives and identified 12 with activities that are eightfold more potent than that of rifalazil. These compounds also showed exceptional activities against rifampin-resistant strains that carry missense mutations in the rpoB gene. The antimicrobial potency and intracellular penetration of these agents suggest their potential in treatment of chlamydial infections.

* Corresponding author. Mailing address: 1959 NE Pacific Street, University of Washington, Box 356523, Seattle, WA 98195. Phone: (206) 616-4170. Fax: (206) 616-4898. E-mail: wes{at}u.washington.edu.

Antimicrobial Agents and Chemotherapy, September 2005, p. 3974-3976, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3974-3976.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Horner, P (2006). The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.. Sex. Transm. Infect. 82: 340-343 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»